Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prolium Bioscience
Delaware, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Prolium Bioscience is a US-based biotech founded and funded by RTW Investments. Its lead asset, ICP-B02 (CM355), a CD20×CD3 bispecific antibody, is in Phase 1/2 trials in China for relapsed/refractory non-Hodgkin lymphoma, showing promising early activity. Prolium has in-licensed global rights for non-oncology indications and ex-Asia oncology indications for ICP-B02 from KeyMed Biosciences and InnoCare Pharma, with plans for dose-expansion and combination studies.
- Therapeutic areas
- OncologyOther
- Modalities
- Bispecific monoclonal antibody
- Industry
- Biotech
02
Partnerships
KeyMed BiosciencesInnoCare PharmaRTW Investments
Beyond the preview
Go deeper on Prolium Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolium Bioscience.